Adaptimmune Presents Detailed Safety Update from Ongoing MAGE-A10 Pilot Studies at ASCO
June 04, 2018 07:30 ET
|
Adaptimmune Therapeutics plc
- Acceptable safety profile with no evidence of off-target toxicity in 100 million cell safety cohorts - - Dosing continues with the one billion “target” cell dose - PHILADELPHIA, Pa. and OXFORD,...
Adaptimmune Announces First Patient to Receive One Billion Target Cell Dose after Positive Safety Data from Pilot Study with MAGE-A4 SPEAR T-cells
June 04, 2018 07:30 ET
|
Adaptimmune Therapeutics plc
- No evidence of off-target toxicity at 100 million cells for second wholly owned asset - - Synovial sarcoma and MRCLS added to the seven solid tumors already in the MAGE-A4 basket study...
Updated Myxoid/Round Cell Liposarcoma Data with NY-ESO, Presented at ASCO Annual Meeting, Further Supports Promising Benefit: Risk Profile
June 02, 2018 08:00 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, June 02, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented initial data from the...
Myxoid/Round Cell Liposarcoma Data with NY-ESO and MAGE-A10 Study Update to be Presented at American Association for Clinical Oncology (ASCO) Annual Meeting
May 16, 2018 17:00 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, U.K., May 16, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will release updated data from ongoing...
Adaptimmune to Report First Quarter 2018 Financial Results and Business Update on Wednesday May 9, 2018
April 25, 2018 08:00 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, U.K., April 25, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the...
Paul Stead Joins Adaptimmune as Vice President of Business Development
January 04, 2018 08:00 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA, Pa. and OXFORD, England, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Paul Stead, B....